Clinical Trial Update: Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the safety and immunogenicity of a tetanus toxoid adsorbed vaccine in adults aged 18-44 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tetanus

Drugs mentioned

• Tetanus Toxoid Adsorbed Vaccine (Tetanus toxoid adsorbed vaccine)

Snippet

Sponsor: Sinovac Life Sciences Co., Ltd. | Conditions: Tetanus | Phase 3 | Status: COMPLETED